12 Februar 2020

DMC Biotech Completes Successful Pilot of L-alanine

The predictability of the DMC process has been demonstrated from high through put screening to commercially relevant scale

DMC Biotechnologies has successfully produced its lead product, L-alanineat pilot scale. Commercial key performance metrics were achieved and performance from the bench scale was also demonstrated at 3m3 scale fermentationand for each of the downstream purification unit operations. The robustness of DMC’s Dynamic Metabolic Control technology to the process environment was also validated.

The predictability of the DMC process has been demonstrated from high through put screening to commercially relevant scale. Kilogram-sized samples of on-specification product are currently being provided to potential customers, paving the way to commercial launch later this year. No further strain improvement or process engineering is required.

During the execution of the fermentation, a technical failure of an inletvalve in the pilot plant resulted in a material deviation from the protocol. This type of mechanical issue is common place in the real world of industrial fermentation. The DMC strain and process were not materially affected by this deviation and the target metrics were still achieved because of the robustness of the technology and the timely response by BPF’s operators. In contrast, most of the current bioprocesses today would have been un-recoverable to this type of deviation.

Raimo van der Linden, Business Development Manager, Bioprocess Pilot Facility (BPF) said, “We recreate real life industrial conditions at BPF and help companies such as DMC validate their technology at pilot scale. The robustness of DMC’s process was thoroughly challenged during this work. The demonstration of robustness to the process environment is truly game-changing for the field of industrial biotechnology.”

Matt Lipscomb, Ph.D., CEO & Co-Founder of DMC said, “Successful pilot scale production is an important step towards full commercialization of L-alanine which will happen later this year. We knew our Dynamic Metabolic Control process was robust. It has been further proven through real-world operating conditions at BPF’spilot plant.”

See the video press release at https://youtu.be/UvJAyllodRo.

Source: DMC Biotechnologies, press release, 2020-02-06.


Share on Twitter+1Share on FacebookShare on XingShare on LinkedInShare via email